Core Insights - Nuwellis, Inc. plans to launch a new 24-hour circuit for Aquadex therapy in the U.S. this fall, designed for single-day outpatient sessions, complementing the existing 72-hour option for multi-day therapy or inpatient care [1][3] - The introduction of the 24-hour circuit aligns with the growing trend of hospitals establishing outpatient Aquadex programs, aiming to provide predictable, scheduled care for patients needing fluid removal without hospital admission [2][3] Company Overview - Nuwellis, Inc. is a medical device company focused on transforming the lives of patients suffering from fluid overload through innovation and collaboration, with a primary focus on the Aquadex SmartFlow system for ultrafiltration therapy [5] - The company is headquartered in Minneapolis and has a wholly owned subsidiary in Ireland [5] Product Details - The Aquadex SmartFlow system is clinically proven for removing excess fluid from patients suffering from hypervolemia, indicated for temporary (up to 8 hours) or extended use in patients weighing 20 kg or more [6] - Treatments must be administered by trained healthcare providers in clinical settings under physician prescription [6]
Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management